|
1
|
Shimokawa T, Matsushima S, Tsunoda T,
Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34,
which shows elevated expression in the majority of human colon
cancers, as a novel drug target. Int J Oncol. 29:381–386.
2006.PubMed/NCBI
|
|
2
|
Uchida N, Tsunoda T, Wada S, Furukawa Y,
Nakamura Y and Tahara H: Ring finger protein 43 as a new target for
cancer immunotherapy. Clin Cancer Res. 10:8577–8586. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matsushita N, Aruga A, Inoue Y, Kotera Y,
Takeda K and Yamamoto M: Phase I clinical trial of a peptide
vaccine combined with tegafur-uracil plus leucovorin for treatment
of advanced or recurrent colorectal cancer. Oncol Rep. 29:951–959.
2013.PubMed/NCBI
|
|
4
|
Hazama S, Nakamura Y, Takenouchi H, Suzuki
N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K,
et al: A phase I study of combination vaccine treatment of five
therapeutic epitope-peptides for metastatic colorectal cancer;
safety, immunological response, and clinical outcome. J Transl Med.
12:632014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yasuda S, Tsuchiya I, Okada K, Tanaka A,
Suzuki T, Sadahiro S, Takeda K, Yamamoto S and Nakui M: Significant
clinical response of advanced colon cancer to peptide vaccine
therapy: A case report. Tokai J Exp Clin Med. 37:57–61.
2012.PubMed/NCBI
|
|
6
|
Okuno K, Sugiura F, Hida JI, Tokoro T,
Ishimaru E, Sukegawa Y and Ueda K: Phase I clinical trial of a
novel peptide vaccine in combination with UFT/LV for metastatic
colorectal cancer. Exp Ther Med. 2:73–79. 2011.PubMed/NCBI
|
|
7
|
Srinivasan M, Sedmak D and Jewell S:
Effect of fixatives and tissue processing on the content and
integrity of nucleic acids. Am J Pathol. 161:1961–1971. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyazono Y, Kamogawa Y, Ryo K, Furukawa T,
Mitsuhashi M, Yamauchi K, Kameoka T and Hayashi N: Effect of
B7.1-transfected human colon cancer cells on the induction of
autologous tumour-specific cytotoxic T cells. J Gastroenterol
Hepatol. 14:997–1003. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Terada KJ, Ueno S, Yomogida K, Imai T,
Kiyonari H, Takeda N, Yano M, Abe S, Aizawa S and Mori M:
Expression of Tom34 splicing isoforms in mouse testis and knockout
of Tom34 in mice. J Biochem. 133:625–631. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chewawiwat N, Yano M, Terada K, Hoogenraad
NJ and Mori M: Characterization of the novel mitochondrial protein
import component, Tom34, in mammalian cells. J Biochem.
125:721–727. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sugiura T, Yamaguchi A and Miyamoto K: A
cancer-associated RING finger protein, RNF43, is a ubiquitin ligase
that interacts with a nuclear protein, HAP95. Exp Cell Res.
314:1519–1528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi N, Yamaguchi K, Ikenoue T, Fujii
T and Furukawa Y: Identification of two Wnt-responsive elements in
the intron of RING finger protein 43 (RNF43) gene. PLoS One.
9:e865822014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shinada K, Tsukiyama T, Sho T, Okumura F,
Asaka M and Hatakeyama S: RNF43 interacts with NEDL1 and regulates
p53-mediated transcription. Biochem Biophys Res Commun.
404:143–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yagyu R, Furukawa Y, Lin YM, Shimokawa T,
Yamamura T and Nakamura Y: A novel oncoprotein RNF43 functions in
an autocrine manner in colorectal cancer. Int J Oncol.
25:1343–1348. 2004.PubMed/NCBI
|
|
16
|
Koo BK, Spit M, Jordens I, Low TY, Stange
DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM
and Clevers H: Tumour suppressor RNF43 is a stem-cell E3 ligase
that induces endocytosis of Wnt receptors. Nature. 488:665–669.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu J, Jiao Y, Dal Molin M, Maitra A, de
Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI,
et al: Whole-exome sequencing of neoplastic cysts of the pancreas
reveals recurrent mutations in components of ubiquitin-dependent
pathways. Proc Natl Acad Sci USA. 108:pp. 21188–21193. 2011;
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ong CK, Subimerb C, Pairojkul C, Wongkham
S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, et
al: Exome sequencing of liver fluke-associated cholangiocarcinoma.
Nat Genet. 44:690–693. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sadanaga N, Nagashima H, Mashino K, Tahara
K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, et
al: Dendritic cell vaccination with MAGE peptide is a novel
therapeutic approach for gastrointestinal carcinomas. Clin Cancer
Res. 7:2277–2284. 2001.PubMed/NCBI
|
|
20
|
Shimizu K, Kotera Y, Aruga A, Takeshita N,
Takasaki K and Yamamoto M: Clinical utilization of postoperative
dendritic cell vaccine plus activated T-cell transfer in patients
with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci.
19:171–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
